Replies to post #2893 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

ENTA’s rationale for securing additional IP in HBV/HDV could be to seek royalties on GILD’s Hepludex rather than to support ENTA’s own HBV program.

Dew, could you explain how they could get royalties from patents they just filed?